AbbVie enters $3.8bn deal with Genmab 11-Jun-2020 By Ben Hargreaves The two companies will collaborate on Genmab’s lead bispecific antibody treatment and develop further candidates.
COVID-19 pandemic is ‘worst nightmare’ scenario, says Fauci 10-Jun-2020 By Ben Hargreaves However, the seriousness of the outbreak will result in multiple vaccines and therapeutics being approved, he suggests.
CMAB completes antibody development for QureBio 10-Jun-2020 By Ben Hargreaves The Chinese CDMO takes bispecific antibody through to IND-stage in nine months.
Oxford Biomedica adds two suites to manufacture AZ vaccine 09-Jun-2020 By Ben Hargreaves Oxford Biomedica teams up with VMIC to expand capacity for AZ’s vaccine candidate for COVID-19.
AZ secures two billion doses of COVID-19 vaccine 05-Jun-2020 By Ben Hargreaves AstraZeneca partners with three organization to boost manufacturing capacity to two billion doses.
US pushes forward five vaccine candidates 04-Jun-2020 By Ben Hargreaves Reports suggest US government has selected five companies with the most promising vaccine leads to be given additional financial and infrastructure support.
CEPI funds trials against emerging infectious disease 03-Jun-2020 By Ben Hargreaves With many organizations pivoting to work on the pandemic, CEPI partners with consortium to develop a vaccine against the Chikungunya virus.
Investigation opened over biotech’s COVID-19 vaccine claim 03-Jun-2020 By Ben Hargreaves A law firm investigates Inovio over claims it developed a vaccine to COVID-19 within three hours.
BARDA provides CDMO $628m to serve US government 02-Jun-2020 By Ben Hargreaves Emergent receives funds to provide manufacturing capabilities to the US government for COVID-19 vaccine candidates.
Novavax expands COVID-19 vaccine manufacturing through acquisition 02-Jun-2020 By Ben Hargreaves Novavax buys Praha Vaccines and gains the capacity to produce over one billion doses of its COVID-19 vaccine candidate.
First antibody treatment designed against COVID-19 hits trials 02-Jun-2020 By Ben Hargreaves Eli Lilly’s potential treatment is the first coronavirus-specific mAb to enter trials and large-scale manufacturing efforts will commence immediately.
Novartis to manufacture partner’s COVID-19 vaccine ‘at no cost’ 01-Jun-2020 By Ben Hargreaves Massachusetts General Hospital readies its vaccine for clinical trials by signing manufacturing agreement with Novartis.
AZ agrees commercial manufacturing deal for COVID-19 vaccine 01-Jun-2020 By Ben Hargreaves Oxford Biomedica signs on to produce clinical and commercial supply of AZD1222, which recently entered late-stage trials.
GSK to ramp up vaccine adjuvant production to 1bn doses 29-May-2020 By Ben Hargreaves The company will supply the adjuvant to partners’ COVID-19 vaccine candidates, without expecting to profit from sales.
Gilead seals $2bn deal for Arcus’ pipeline 28-May-2020 By Ben Hargreaves Gilead signs 10-year deal with Arcus to gain access to its clinical and preclinical pipeline of immuno-oncology candidates.
